

Investor Webinar: Dr Kyle Hogarth

16 September 2025

Melbourne, Australia, 16 September 2025 – 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”), a global leader in respiratory imaging technology, is pleased to invite shareholders to attend an exclusive webinar featuring a fireside chat between Dr Kyle Hogarth, Professor of Medicine at The University of Chicago, and Tom Godfrey, Senior Healthcare Analyst at Ord Minnett.

About the session

This session provides shareholders with a valuable opportunity to hear directly from Tom Godfrey, Ord Minnett's Senior Healthcare Analyst, as he speaks with Dr Kyle Hogarth, discussing:

- The 4DMedical product suite and its clinical applications;
- How Dr Hogarth utilises key 4DMedical products in clinical practice at UChicago Medicine;
- The advantages of 4DMedical's technology versus legacy diagnostic methods;
- The real-world clinical outcomes and patient benefits; and
- The future of respiratory imaging and 4DMedical's role in transforming lung care.

Featured speaker profile

Dr Kyle Hogarth, MD, FCCP is a Professor of Medicine in the Section of Pulmonary and Critical Care Medicine at The University of Chicago, and the Co-Director of the Lung Cancer Screening Program. Dr Hogarth is an interventional pulmonology specialist and Director of Bronchoscopy at UChicago Medicine, with extensive expertise in the minimally invasive diagnosis, management, staging and treatment of lung cancer.

Dr. Hogarth received his medical degree at Case Western Reserve University School of Medicine and completed a residency in Internal Medicine, and a fellowship in Pulmonary and Critical Care, at The University of Chicago. He has been published in the New England Journal of Medicine, Chest, ERJ and many other journals. Dr Hogarth serves on the editorial board of CHEST (American College of Chest Physicians) and is a founding member and the past President of the Society for Advanced Bronchoscopy.

Webinar details, tomorrow 12:00 pm

Date: Wednesday, 17 September 2025

Time: 12:00 pm – 12:45 pm AEST

Access: You can join the Microsoft Teams meeting [here](#).

This webinar provides a unique opportunity for shareholders to gain insights directly from a leading clinician who is actively using 4DMedical's technology in one of the world's premier academic medical centres. There will also be an opportunity for participants to submit questions.

—ENDS—

Authorised by the 4DMedical Board of Directors.



Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology**[®] transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS[®])**, **CT LVAS[™]**, and the ground-breaking **CT:VQ[™]** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com